CA2882594C - Antibodies to risperidone and use thereof - Google Patents
Antibodies to risperidone and use thereof Download PDFInfo
- Publication number
- CA2882594C CA2882594C CA2882594A CA2882594A CA2882594C CA 2882594 C CA2882594 C CA 2882594C CA 2882594 A CA2882594 A CA 2882594A CA 2882594 A CA2882594 A CA 2882594A CA 2882594 C CA2882594 C CA 2882594C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid residues
- sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title claims abstract description 202
- 229960001534 risperidone Drugs 0.000 title claims abstract description 201
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims abstract description 71
- 229960004372 aripiprazole Drugs 0.000 claims abstract description 70
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims abstract description 67
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims abstract description 67
- 229960005017 olanzapine Drugs 0.000 claims abstract description 66
- 229960004431 quetiapine Drugs 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 63
- 238000003556 assay Methods 0.000 claims abstract description 45
- 238000001514 detection method Methods 0.000 claims abstract description 23
- 238000002967 competitive immunoassay Methods 0.000 claims abstract description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 610
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 199
- 239000012634 fragment Substances 0.000 claims description 104
- 230000027455 binding Effects 0.000 claims description 84
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 51
- 230000009137 competitive binding Effects 0.000 claims description 48
- 229960001057 paliperidone Drugs 0.000 claims description 48
- 239000002207 metabolite Substances 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 18
- 239000000164 antipsychotic agent Substances 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 14
- 238000003018 immunoassay Methods 0.000 claims description 12
- 238000003149 assay kit Methods 0.000 claims description 11
- 238000012544 monitoring process Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 230000008406 drug-drug interaction Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 96
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 96
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 96
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 95
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 95
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1203
- 239000002773 nucleotide Substances 0.000 description 384
- 125000003729 nucleotide group Chemical group 0.000 description 383
- 238000006243 chemical reaction Methods 0.000 description 91
- 239000000523 sample Substances 0.000 description 83
- 230000000875 corresponding effect Effects 0.000 description 54
- 231100000673 dose–response relationship Toxicity 0.000 description 52
- 210000004408 hybridoma Anatomy 0.000 description 48
- 230000000561 anti-psychotic effect Effects 0.000 description 23
- 239000003196 psychodysleptic agent Substances 0.000 description 20
- 230000009471 action Effects 0.000 description 18
- 239000012491 analyte Substances 0.000 description 17
- 239000013641 positive control Substances 0.000 description 14
- 108050007001 Cytochrome b6-f complex iron-sulfur subunit Proteins 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- KRTLKZNAWAMORA-UUCOHRQLSA-N (3s,10s,13r,14r,17r)-17-[(2r)-4-(3,3-dimethyloxiran-2-yl)butan-2-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCC3=C(CCC4C(C)(C)[C@@H](O)CC[C@@]43C)[C@]2(C)CC1)C)CC1OC1(C)C KRTLKZNAWAMORA-UUCOHRQLSA-N 0.000 description 7
- -1 13-galactosidase Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000002860 competitive effect Effects 0.000 description 6
- 230000009260 cross reactivity Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 201000000980 schizophrenia Diseases 0.000 description 6
- 238000007792 addition Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ABWPQNZPAOAQSG-UHFFFAOYSA-N 7-Hydroxyrisperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CC(O)CCC4=NC=3C)=NOC2=C1 ABWPQNZPAOAQSG-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- OTJMDLIUFVHKNU-UHFFFAOYSA-N 2-hydroxy-5-methylidene-3-(piperidin-1-ylamino)cyclopent-2-en-1-one Chemical compound C1C(=C)C(=O)C(O)=C1NN1CCCCC1 OTJMDLIUFVHKNU-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101001030284 Homo sapiens Methylthioribulose-1-phosphate dehydratase Proteins 0.000 description 2
- 101100519421 Homo sapiens PDZD11 gene Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100038593 Methylthioribulose-1-phosphate dehydratase Human genes 0.000 description 2
- 102100025661 PDZ domain-containing protein 11 Human genes 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 101710128746 Cytochrome b6-f complex iron-sulfur subunit 1 Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101150042916 FSF1 gene Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001020548 Homo sapiens LIM/homeobox protein Lhx1 Proteins 0.000 description 1
- 101000976913 Homo sapiens Lens fiber major intrinsic protein Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102100023487 Lens fiber major intrinsic protein Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 101100202924 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tsp-2 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- HUTDUHSNJYTCAR-UHFFFAOYSA-N ancymidol Chemical compound C1=CC(OC)=CC=C1C(O)(C=1C=NC=NC=1)C1CC1 HUTDUHSNJYTCAR-UHFFFAOYSA-N 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691675P | 2012-08-21 | 2012-08-21 | |
| US61/691,675 | 2012-08-21 | ||
| US201361790880P | 2013-03-15 | 2013-03-15 | |
| US61/790,880 | 2013-03-15 | ||
| PCT/US2013/055803 WO2014031648A2 (en) | 2012-08-21 | 2013-08-20 | Antibodies to risperidone and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2882594A1 CA2882594A1 (en) | 2014-02-27 |
| CA2882594C true CA2882594C (en) | 2019-07-16 |
Family
ID=50148309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2882594A Active CA2882594C (en) | 2012-08-21 | 2013-08-20 | Antibodies to risperidone and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9664700B2 (enExample) |
| EP (3) | EP2888593B1 (enExample) |
| JP (3) | JP6339569B2 (enExample) |
| CN (2) | CN104737017B (enExample) |
| AU (2) | AU2013305887B2 (enExample) |
| CA (1) | CA2882594C (enExample) |
| ES (2) | ES2691092T3 (enExample) |
| PL (2) | PL3462173T3 (enExample) |
| PT (2) | PT3462173T (enExample) |
| TR (1) | TR201816416T4 (enExample) |
| WO (1) | WO2014031648A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882555C (en) | 2012-08-21 | 2018-11-06 | Janssen Pharmaceutica Nv | Haptens of paliperidone |
| PT2888284T (pt) | 2012-08-21 | 2022-11-18 | Janssen Pharmaceutica Nv | Anticorpos dirigidos contra haptenos de risperidona e a sua utilização |
| TR201910347T4 (tr) | 2012-08-21 | 2019-07-22 | Janssen Pharmaceutica Nv | Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı. |
| JP6389176B2 (ja) | 2012-08-21 | 2018-09-12 | ヤンセン ファーマシューティカ エヌ．ベー． | アリピプラゾールハプテンに対する抗体及びその使用 |
| EP3663316A1 (en) | 2012-08-21 | 2020-06-10 | Janssen Pharmaceutica NV | Antibodies to aripiprazole and use thereof |
| EP2888287A4 (en) | 2012-08-21 | 2016-04-20 | Ortho Clinical Diagnostics Inc | ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE |
| HK1211958A1 (en) * | 2012-08-21 | 2016-06-03 | Ortho-Clinical Diagnostics, Inc. | Antibodies to paliperidone and use thereof |
| AU2013305901B2 (en) | 2012-08-21 | 2017-10-26 | Saladax Biomedical Inc. | Antibodies to olanzapine and use thereof |
| PT2888234T (pt) | 2012-08-21 | 2018-02-22 | Janssen Pharmaceutica Nv | Haptenos de aripiprazol e seu uso em imunoensaios |
| CN104737017B (zh) | 2012-08-21 | 2017-03-08 | 詹森药业有限公司 | 利培酮的抗体及其用途 |
| EP2888592B1 (en) | 2012-08-21 | 2017-11-08 | Janssen Pharmaceutica NV | Antibodies to quetiapine and use thereof |
| PL3385284T3 (pl) | 2012-08-21 | 2020-09-21 | Janssen Pharmaceutica Nv | Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie |
| EP3283883B1 (en) | 2015-04-13 | 2020-02-26 | Teknologian Tutkimuskeskus VTT OY | Lateral flow device, assay device and kit and method for analyzing a fluid sample |
| CA3008809A1 (en) * | 2015-12-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
| WO2017106508A1 (en) | 2015-12-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Antibodies to quetiapine and use thereof |
| CN106611517B (zh) * | 2016-08-12 | 2020-04-24 | 简极科技有限公司 | 一种球类战术演示方法和装置 |
| CN110938072A (zh) * | 2019-10-30 | 2020-03-31 | 杭州博拓生物科技股份有限公司 | 一种利培酮人工抗原及其制备方法 |
| WO2022226079A1 (en) * | 2021-04-20 | 2022-10-27 | Inbios International, Inc. | Neutralizing antibodies against sars-cov-2 |
| CN114957456B (zh) * | 2022-05-28 | 2024-03-12 | 浙江大学医学院附属第一医院 | 甲型流感病毒血凝素蛋白的单克隆抗体zju-a1a3及其在检测中的应用 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| EP1248112A3 (en) | 1987-04-27 | 2004-08-25 | Inverness Medical Switzerland GmbH | Immunochromatographic specific binding assay device |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
| ATE204385T1 (de) | 1991-06-07 | 2001-09-15 | Johnson & Johnson Clin Diag | Immunoassays unter verwendung von markierten hapten-analogen |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| ES2153373T3 (es) | 1992-05-29 | 2001-03-01 | Lilly Co Eli | Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central. |
| US6034078A (en) | 1992-05-29 | 2000-03-07 | Eli Lilly And Company Limited | Thienobenzodiazepine compounds |
| US5642870A (en) | 1992-08-05 | 1997-07-01 | Sargis; Ike | Switch stand |
| US5395933A (en) | 1992-08-07 | 1995-03-07 | Eastman Kodak Company | Carbamazepine hapten analogues |
| CZ293764B6 (cs) | 1993-11-19 | 2004-07-14 | Janssen Pharmaceutica N. V. | Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití |
| EP0804580B1 (en) | 1994-06-10 | 2008-10-08 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein c |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5761894A (en) | 1996-09-25 | 1998-06-09 | Magic Circle Corporation | Grass striping attachment for lawn mowers |
| WO1998059233A1 (en) | 1997-06-23 | 1998-12-30 | Luminex Corporation | Interlaced lasers for multiple fluorescence measurement |
| US6830731B1 (en) | 1998-01-05 | 2004-12-14 | Biosite, Inc. | Immunoassay fluorometer |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| US20030143233A1 (en) | 1999-06-07 | 2003-07-31 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6958156B2 (en) | 2000-12-15 | 2005-10-25 | Vyrex Corporation | Isoflavone derivatives |
| DK2371861T3 (da) * | 2002-01-25 | 2017-11-20 | Novo Nordisk As | Monoklonale antistoffer mod ekstracellulære løkker af C5aR |
| EP1333023B1 (en) | 2002-01-31 | 2010-12-22 | Randox Laboratories Ltd. | Immunogens, antibodies and conjugates to ketamine and its metabolites |
| JP2005526044A (ja) | 2002-02-21 | 2005-09-02 | デューク ユニバーシティ | 抗ｃｄ２２抗体を使用した治療方法 |
| DE60318030T2 (de) | 2002-03-28 | 2008-04-10 | Eli Lilly And Co., Indianapolis | Piperazine-substituierte aryl-benzodiazepine und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychosen |
| SE0201738D0 (sv) | 2002-06-07 | 2002-06-07 | Aamic Ab | Micro-fluid structures |
| US20040127489A1 (en) | 2002-07-29 | 2004-07-01 | David Pickar | Novel antipsychotic combination therapies and compositions useful therein |
| ATE361289T1 (de) | 2002-08-05 | 2007-05-15 | Lilly Co Eli | Piperazinsubstituierte arylbenzodiazepine |
| US7271252B2 (en) | 2003-04-22 | 2007-09-18 | Roche Diagnostics Operations, Inc. | Reagents for detecting efavirenz |
| CA2525251C (en) | 2003-05-09 | 2015-10-27 | Duke University | Cd20-specific antibodies and methods employing same |
| AU2004265021B2 (en) | 2003-08-18 | 2010-05-27 | H. Lundbeck A/S | Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
| EP1664007B1 (en) | 2003-09-23 | 2009-12-23 | Fermion Oy | Preparation of quetiapine |
| JP4976134B2 (ja) | 2003-10-01 | 2012-07-18 | アドラー コーポレーション | スピロ環複素環誘導体及びそれらを使用する方法 |
| CN1870980B (zh) * | 2003-10-23 | 2010-06-23 | 大冢制药株式会社 | 控释无菌阿立哌唑注射剂和方法 |
| GB0328892D0 (en) * | 2003-12-12 | 2004-01-14 | Inverness Medical Switzerland | Positive signal assay for analytes |
| AU2004298660B2 (en) * | 2003-12-12 | 2010-04-22 | Abbott Rapid Diagnostics International Unlimited Company | Assay |
| SE0400662D0 (sv) | 2004-03-24 | 2004-03-24 | Aamic Ab | Assay device and method |
| WO2005103250A1 (ja) | 2004-04-26 | 2005-11-03 | Takami Matsuyama | 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬 |
| SE527036C2 (sv) | 2004-06-02 | 2005-12-13 | Aamic Ab | Analysanordning med reglerat flöde och motsvarande förfarande |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| US20060235005A1 (en) | 2005-04-14 | 2006-10-19 | Oak Labs, Corp. | Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia |
| CA2607475A1 (en) * | 2005-04-22 | 2006-11-02 | Genentech, Inc. | Method for treating dementia or alzheimer's disease with a cd20 antibody |
| JP5249748B2 (ja) | 2005-04-25 | 2013-07-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造 |
| SE529254C2 (sv) | 2005-06-17 | 2007-06-12 | Aamic Ab | Optiskt testsystem |
| SE528233C2 (sv) | 2005-06-20 | 2006-09-26 | Aamic Ab | Metod och medel för att åstadkomma vätsketransport |
| SE529711C2 (sv) | 2006-03-22 | 2007-11-06 | Aamic Ab | Fluorescensläsare |
| CN101589059A (zh) * | 2006-10-20 | 2009-11-25 | 株式会社未来创药研究所 | 包含抗hb-egf抗体作为活性成分的药物组合物 |
| US8975374B2 (en) * | 2006-10-20 | 2015-03-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
| WO2008047925A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| JP2010507648A (ja) * | 2006-10-25 | 2010-03-11 | ラモット アット テル−アビブ ユニバーシティー リミテッド | グルタミン酸ｎｍｄａ活性を有する新規向精神薬 |
| US20080138842A1 (en) * | 2006-12-11 | 2008-06-12 | Hans Boehringer | Indirect lateral flow sandwich assay |
| WO2008072723A1 (ja) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断 |
| CA2672972C (en) | 2006-12-29 | 2015-06-23 | Abbott Laboratories | Diagnostic test for the detection of a molecule or drug in whole blood |
| WO2008087557A2 (en) | 2007-01-08 | 2008-07-24 | Actavis Group Ptc Ehf | An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride |
| CN101245065B (zh) | 2007-02-14 | 2010-05-19 | 江苏恩华药业股份有限公司 | 制备苯并异噁唑衍生物的方法及其中间体 |
| KR20100075455A (ko) | 2007-09-27 | 2010-07-02 | 노파르티스 아게 | 약물 모니터링 분석법 |
| WO2010104749A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
| MX2011000875A (es) | 2008-07-21 | 2011-04-05 | Probiodrug Ag | Ensayo de anticuerpo de diagnostico. |
| US20110207718A1 (en) | 2008-08-06 | 2011-08-25 | Gosforth Centre (Holdings) Pty Ltd. | Compositions and methods for treating psychiatric disorders |
| WO2010033270A1 (en) | 2008-09-17 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors |
| JP5749169B2 (ja) | 2008-10-14 | 2015-07-15 | アストラゼネカ アクチボラグ | 細菌感染の処置用の縮合スピロ環式ヘテロ芳香族化合物 |
| CA2742074A1 (en) | 2008-10-29 | 2010-08-26 | Janssen Pharmaceutica Nv | Methods of treating psychosis and schizophrenia based on polymorphisms in the erbb4 gene |
| EP2194048A1 (en) | 2008-12-02 | 2010-06-09 | Dirk Sartor | Nitrate esters for the treatment of vascular and metabolic diseases |
| US8480333B2 (en) | 2008-12-26 | 2013-07-09 | Steven Edward DeMay | Frame rail assemblies and interlocking frame rail systems |
| EP2389169A1 (en) | 2009-01-26 | 2011-11-30 | Egalet A/S | Controlled release formulations with continuous efficacy |
| NZ597108A (en) | 2009-06-25 | 2014-04-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds |
| EP2451844B1 (en) * | 2009-07-10 | 2015-04-22 | Innate Pharma | Tlr3 binding agents |
| JP5904941B2 (ja) | 2009-07-31 | 2016-04-20 | アセンディス ファーマ エー／エス | 生物分解性ポリエチレングリコール系水不溶性ヒドロゲル |
| US20120282173A1 (en) | 2009-08-17 | 2012-11-08 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| WO2011042450A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Carrier linked paliperidone prodrugs |
| EP2343296A1 (en) | 2009-12-01 | 2011-07-13 | Chemo Ibérica, S.A. | A process for the purification of paliperidone |
| CN107714703A (zh) | 2009-12-31 | 2018-02-23 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
| TR201900067T4 (tr) | 2010-03-11 | 2019-02-21 | Kempharm Inc | Ketiyapinin yağ asidi konjugatları, bunların yapılmasına ve kullanılmasına yönelik proses. |
| US8114621B2 (en) | 2010-03-12 | 2012-02-14 | Saladax Biomedical Inc. | Lenalidomide and thalidomide immunoassays |
| US8088594B2 (en) * | 2010-03-16 | 2012-01-03 | Saladax Biomedical Inc. | Risperidone immunoassay |
| WO2011159537A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Method and device for analyte detection |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| JP5848761B2 (ja) | 2010-06-24 | 2016-01-27 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体 |
| WO2012003418A2 (en) | 2010-07-02 | 2012-01-05 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine d2 receptors |
| US8623324B2 (en) | 2010-07-21 | 2014-01-07 | Aat Bioquest Inc. | Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates |
| HUE031855T2 (en) * | 2010-08-20 | 2017-08-28 | Novartis Ag | Anti-epidermal growth factor receptor 3 (HER3) antibodies |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| AU2012296949B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| CA2843503C (en) | 2011-08-12 | 2020-12-22 | Ulrich Hersel | Polymeric hyperbranched carrier-linked prodrugs |
| CA2858787C (en) | 2011-12-15 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of tertiary amine compounds |
| WO2014028800A1 (en) | 2012-08-16 | 2014-02-20 | Janssen Pharmaceutica Nv | Substituted pyrazoles as n-type calcium channel blockers |
| EP2888287A4 (en) | 2012-08-21 | 2016-04-20 | Ortho Clinical Diagnostics Inc | ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE |
| JP6131500B2 (ja) * | 2012-08-21 | 2017-05-24 | ヤンセン ファーマシューティカ エヌ．ベー． | リスペリドン及びパリペリドンのハプテン |
| PT2888284T (pt) | 2012-08-21 | 2022-11-18 | Janssen Pharmaceutica Nv | Anticorpos dirigidos contra haptenos de risperidona e a sua utilização |
| EP3663316A1 (en) | 2012-08-21 | 2020-06-10 | Janssen Pharmaceutica NV | Antibodies to aripiprazole and use thereof |
| PL3385284T3 (pl) | 2012-08-21 | 2020-09-21 | Janssen Pharmaceutica Nv | Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie |
| CA2882555C (en) | 2012-08-21 | 2018-11-06 | Janssen Pharmaceutica Nv | Haptens of paliperidone |
| US9303041B2 (en) | 2012-08-21 | 2016-04-05 | Janssen Pharmaceutica Nv | Haptens of olanzapine |
| JP6389176B2 (ja) | 2012-08-21 | 2018-09-12 | ヤンセン ファーマシューティカ エヌ．ベー． | アリピプラゾールハプテンに対する抗体及びその使用 |
| EP2888592B1 (en) | 2012-08-21 | 2017-11-08 | Janssen Pharmaceutica NV | Antibodies to quetiapine and use thereof |
| EP2888257B1 (en) | 2012-08-21 | 2017-08-02 | Janssen Pharmaceutica NV | Haptens of quetiapine for use in immunoassays |
| AU2013305901B2 (en) | 2012-08-21 | 2017-10-26 | Saladax Biomedical Inc. | Antibodies to olanzapine and use thereof |
| CN104737017B (zh) | 2012-08-21 | 2017-03-08 | 詹森药业有限公司 | 利培酮的抗体及其用途 |
| PT2888234T (pt) | 2012-08-21 | 2018-02-22 | Janssen Pharmaceutica Nv | Haptenos de aripiprazol e seu uso em imunoensaios |
| TR201910347T4 (tr) | 2012-08-21 | 2019-07-22 | Janssen Pharmaceutica Nv | Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı. |
| HK1211958A1 (en) * | 2012-08-21 | 2016-06-03 | Ortho-Clinical Diagnostics, Inc. | Antibodies to paliperidone and use thereof |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| CA3008809A1 (en) | 2015-12-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
-
2013
- 2013-08-20 CN CN201380054930.9A patent/CN104737017B/zh not_active Expired - Fee Related
- 2013-08-20 US US13/971,499 patent/US9664700B2/en not_active Expired - Fee Related
- 2013-08-20 PT PT181952151T patent/PT3462173T/pt unknown
- 2013-08-20 JP JP2015528592A patent/JP6339569B2/ja not_active Expired - Fee Related
- 2013-08-20 CA CA2882594A patent/CA2882594C/en active Active
- 2013-08-20 PL PL18195215T patent/PL3462173T3/pl unknown
- 2013-08-20 ES ES13831744.1T patent/ES2691092T3/es active Active
- 2013-08-20 EP EP13831744.1A patent/EP2888593B1/en active Active
- 2013-08-20 AU AU2013305887A patent/AU2013305887B2/en not_active Ceased
- 2013-08-20 EP EP18195215.1A patent/EP3462173B1/en active Active
- 2013-08-20 PT PT13831744T patent/PT2888593T/pt unknown
- 2013-08-20 EP EP21160747.8A patent/EP3933406A3/en not_active Withdrawn
- 2013-08-20 WO PCT/US2013/055803 patent/WO2014031648A2/en not_active Ceased
- 2013-08-20 ES ES18195215T patent/ES2870004T3/es active Active
- 2013-08-20 CN CN201611019067.5A patent/CN107043424B/zh not_active Expired - Fee Related
- 2013-08-20 TR TR2018/16416T patent/TR201816416T4/tr unknown
- 2013-08-20 PL PL13831744T patent/PL2888593T3/pl unknown
-
2017
- 2017-05-08 US US15/589,685 patent/US10690686B2/en not_active Expired - Fee Related
-
2018
- 2018-03-05 JP JP2018038402A patent/JP2018127456A/ja active Pending
- 2018-05-21 AU AU2018203561A patent/AU2018203561B2/en not_active Ceased
-
2020
- 2020-04-03 JP JP2020067529A patent/JP2020143059A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2882594C (en) | Antibodies to risperidone and use thereof | |
| AU2019284031B2 (en) | Antibodies to aripiprazole and use thereof | |
| AU2019283820B2 (en) | Antibodies to olanzapine and use thereof | |
| AU2018202554B2 (en) | Antibodies to quetiapine and use thereof | |
| US11385246B2 (en) | Antibodies to paliperidone and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160203 |